Retiring Chair of UNC Biostatistics, Lisa LaVange (@LavangeLisa), and UNC Biostatistics (UNC Biostatistics) Alumnus, Ben Saville, presented a short course at the ASA Biopharmaceutical (@ASABiopharm) Section's Regulatory Industry Statistics Workshop (RISW) last week #ASABiopharm

Great example of an adaptive trial design with population enrichment. The trial enrolled ICH patients in both Lobar and ABG regions, and the adaptive algorithm enriched to the Lobar location early. Significant primary analysis and first RCT to show benefit of MIPS!

I should have mentioned FACTS software for simulating adaptive designs! berryconsultants.com/software/facts/

This week's spotlight post features RECOM member Dr. Ben Saville! Find out Ben Saville 's favorite software for conducting Bayesian analyses and his advice for the next generation of statisticians in our post! 😁

Ben Saville and colleagues propose modeling of temporal drift to account for time effects when analyzing platform trials. Ben Saville SCTorg Berry Consultants @statberry Kert Viele @berryni
journals.sagepub.com/doi/pdf/10.117…

Tyler Saville has earned the Bee Cave Raiders Athletics Iron Man Award. Tyler kept getting better and better throughout the year. To see his confidence grow this year has been amazing. Way to out work the competition all year Tyler! BCMS Raiders

This Friday in #COVID19 Grand Rounds, we welcome Dr. Chris Butler of OxPrimaryCareSci and Dr. Ben Saville of Berry Consultants to learn about PRINCIPLE, an adaptive platform trial for community treatment of COVID-19. Join us! #pctGR ⤵️ bit.ly/3w9dFbs

BREAKING NEWS: PRINCIPLE trial reports the corticosteroid budesonide is the first widely available, inexpensive drug found to shorten recovery time in non-hospitalised patients with COVID-19. It is now available in UK #primarycare on a case-by-case basis.
principletrial.org/news/asthma-dr…

. Hrithik Roshan You tweeted my first post on #Coronavirus . Thank you. You massively contributed to spread the message.

I have a new article to help governments know what decisions to make:
medium.com/@tomaspueyo/co…

It makes it clear that the only viable option is Suppression.

Bayesian response adaptive platform trial in The Lancet investigating oseltamivir. Congrats Ben Saville @RogerJLewis JasonConnor and entire team!

thelancet.com/journals/lance…

That's me! twitter.com/AmstatNews/sta…